Strides Q4 revenues up by 40pc
Bangalore, Feb 28 : Strides Arcolab, a global pharmaceutical company, on Thursday announced its financial results for the year ended December 31, 2012.
"2012 has been a satisfying year magnified by operating leverage in both Agila and Pharma businesses with continued compliances across all manufacturing facilities globally and a profound regulatory filing programme," said Arun Kumar, Vice Chairman & Group CEO, Strides Arcolab Limited.
Group Performance Highlights for Q4'12
· Reported Revenues at Rs.648 Crores and Reported EBITDA at Rs.143 Crores, EBITDA Margin of 22%
· Adjusted for Exchange Loss of Rs.20 Crores, EBITDA at Rs.163 Crores, EBITDA Margin of 25%
· Licensing Income impacted by Rs.48 Crores as the company bought back key product portfolios
· Profit before Taxes at Rs.77 Crores (Rs.87 Crores in Q4'11)
· Profit after Taxes at Rs.61 Crores (Rs.68 Crores in Q4'11)
Group Performance Highlights for 2012
· Reported Revenues at Rs. 2,336 Crores and Reported EBITDA at Rs.564 Crores, EBITDA Margin of 24%
· Adjusted for Exchange Loss of Rs.52 Crores, EBITDA at Rs.616 Crores, EBITDA Margin of 26%
· Licensing Income impacted by Rs.64 Crores as the company bought back key product portfolios
· Profit before Taxes at Rs.950 Crores (Rs.273 Crores in 2011)
· Profit after Taxes at Rs.846 Crores (Rs.225 Crores in 2011)
Division Wise Analysis
Agila Specialties Q4'12 Performance Snapshot
Total Revenues at Rs. 365 Crores (Rs.285 Crores in Q4'11), with EBITDA of Rs. 115 Crores (Rs.70 Crores in Q4'11)
- Operational Revenues excluding Brazil at Rs.236 Crores (Rs. 70 Crores in Q4'11), up by 237% with EBITDA Margin of 45% (above guidance range of 23% to 30%)
- Operational Revenues grew by 151% to Rs.307 Crores (Rs.122 Crores in Q4'11) with EBITDA Margin of 32% (above guidance range of 23% to 30%)
- Licensing Revenues of Rs.58 Crores in Q4'12 (Rs.163 Crores in Q4'11)
- Licensing Revenues impacted by Rs.29 Crores as the company bought back key product portfolios
46% of Operational Revenues from North America, 27% from Latin America and 27% from the rest of the world in Q4'12
Agila Specialties 2012 Performance Snapshot
Total Revenues at Rs. 1,365 Crores (Rs.1,032 Crores in 2011), with EBITDA of Rs. 459 Crores (Rs.261 Crores in 2011), EBITDA Margin of 34%
- Operational Revenues excluding Brazil at Rs.798 Crores (Rs.391 Crores in 2011), up by 104% with EBITDA Margin of 36% (above guidance range of 23% to 30%)
- Operational Revenues grew by 76% to Rs.1089 Crores (Rs.616 Crores in 2011) with EBITDA Margin of 27% (in guidance range of 23% to 30%)
- Licensing Revenues of Rs.276 Crores in 2012 (Rs.417 Crores in 2011)
- Licensing Revenues impacted by Rs.45 Crores as the company bought back key product portfolios
40% of Operational Revenues from North America, 30% from Latin America and 30% from the rest of the world in Q4'12
Pharma Q4'12 Performance Snapshot
Total Revenues excluding divested Ascent Australasian Operations at Rs.284 Crores (Rs.178 Crores in Q4'11), with EBITDA of Rs.28 Crores (Rs.14 Crores in Q4'11)
- Operational Revenues excluding Ascent Operations grew by 58% to Rs.271 Crores (Rs.172 Crores in Q4'11) with EBITDA Margin at 18%
- Licensing Revenues of Rs.13 Crores in Q4'12 (Rs.6 Crores in Q4'11)
- Licensing Revenues impacted by Rs.19 Crores as the company bought back key range of immunosuppressants which the company expects to launch on its own in Q2'13
Pharma 2012 Performance Snapshot
Total Revenues excluding divested Ascent Australasian Operations at Rs.926 Crores (Rs.716 Crores in 2011), with EBITDA of Rs.103 Crores (Rs.152 Crores in 2011)
- Operational Revenues excluding Ascent Operations grew by 46% to Rs.883 Crores (Rs.605 Crores in 2011) with EBITDA Margin at 13%
- Licensing Revenues of Rs.43 Crores in 2012 (Rs.111 Crores in 2011)
- Licensing Revenues impacted by Rs.19 Crores as the company bought back key range of immunosuppressants which the company expects to launch on its own in the US market in Q2'13
The company said it recommends a dividend of Rs. 2.00 per share for the year ended December 31, 2012.